Compare Mesoblast Limited (MESO) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Tapestry, Inc. — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while Tapestry, Inc. trades at $161.95 (market cap $33.29B). The key difference: Tapestry, Inc. is far larger — about 15.4× Mesoblast Limited's market cap, and Tapestry, Inc. pays a 0.97% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | TPR | |
|---|---|---|
Market Cap | $2.16B | $33.29B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $164.78 |
52-Week Low | $12.88 | $95.69 |
Enterprise Value | $2.17B | $36.15B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
TPR trades at $162.36, up 0.22% today, and is near its 52-week high with strong bullish technical signals. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.66 exceeding the $1.30 estimate. Recent news highlights AI integration and brand momentum, while analyst consensus is strongly bullish with a $190.33 price target.
Outlook remains positive driven by earnings growth and strategic initiatives, but risks include high valuation multiples and volatile cash flows. The stock offers upside to analyst targets but faces margin pressure and competitive challenges in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
